In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02380-17. doi: 10.1128/AAC.02380-17. Print 2018 May.


The pleuromutilin antibiotic lefamulin demonstrated in vitro activity against the most relevant bacterial pathogens causing sexually transmitted infections (STI), including Chlamydia trachomatis (MIC50/90, 0.02/0.04 mg/liter; n = 15), susceptible and multidrug-resistant Mycoplasma genitalium (MIC range, 0.002 to 0.063 mg/liter; n = 6), and susceptible and resistant Neisseria gonorrhoeae (MIC50/90, 0.12/0.5 mg/liter; n = 25). The results suggest that lefamulin could be a promising first-line antibiotic for the treatment of STI, particularly in populations with high rates of resistance to standard-of-care antibiotics.

Keywords: Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae; lefamulin; pleuromutilin; sexually transmitted diseases; sexually transmitted infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Chlamydia trachomatis / drug effects*
  • Diterpenes / pharmacology
  • Mycoplasma genitalium / drug effects*
  • Neisseria gonorrhoeae / drug effects*
  • Polycyclic Compounds
  • Sexually Transmitted Diseases / microbiology
  • Thioglycolates / pharmacology


  • Anti-Infective Agents
  • Diterpenes
  • Polycyclic Compounds
  • Thioglycolates
  • pleuromutilin
  • lefamulin